Sáiz-Marenco R, Campanario-Pérez R, Amores-Bermúdez J, Arroyo-Maestre JM, Juárez-Soto Á

Language: Spanish
References: 19
Page: 1-14
PDF size: 632.18 Kb.

ABSTRACT

Objectives: The evaluation of quality of life associated with different treatments in patients with prostate cancer is a key factor in making informed therapeutic decisions. Nevertheless, results in clinical practice are heterogeneous and insufficient.
Material and methods: A prospective, observational study was conducted on patients that were going to begin treatment with external beam radiotherapy or laparoscopic radical prostatectomy (LPR) due to localized prostate cancer. The EPIC-CP quality of life questionnaire was completed before starting treatment (baseline) and then 6, 12, and 24 months after treatment.
Results: Fifty-nine patients were included in the analysis: 34 (58%) underwent radical prostatectomy and 25 (42%) received radiotherapy. Mean quality of life worsened in the two treatment groups and in all the domains. Maximum decline was at 6 months, and normal scores were recovered at 24 months. At months 6 and 12 after treatment, the percentage of patients that experienced a minimal important difference in quality of life was significantly higher in the LPR group than in the radiotherapy group for the incontinence and sexual function domains. There was no difference between the two groups at 24 months.
Discussion: Minimal important difference could be calculated using the EPIC-CP questionnaire, thus facilitating the clinical interpretation of the results.
Conclusions: At the medium term, LPR and radiotherapy had a different impact on the quality of life associated with incontinence and sexual function. At 24 months after treatment, quality of life was restored, regardless of treatment.

REFERENCES

1. World Health Organization. Global Cancer Observatory. International Agency for Research on Cancer; 2019.

2. Sociedad Española de Oncología Médica. Cifras del cáncer en España | SEOM - Día Mundial del Cáncer 2020. Sociedad Española de Oncología Médica. 2020.

3. Ministerio de Sanidad y Consumo. Guía de Práctica Clínica sobre Tratamiento de Cáncer de Próstata. Instituto Aragonés de Ciencias de la Salud; 2008.

4. Mottet N, Cornford P, Bergh R van den, Briers E, De Santis M, Fanti S, et al. Prostate Cancer. EUA Guidelines.; 2019.

5. Lardas M, Liew M, van den Bergh RC, De Santis M, Bellmunt J, Van den Broeck T, et al. Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. Eur Urol. 2017;72(6):869– 85. doi: 10.1016/j.eururo.2017.06.035

6. Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol. 2011;186(3):865–72. doi: 10.1016/j.juro.2011.04.085

7. Howell D, Stevens S, Haji F, Ismail Z, Brundage MD. Evaluation of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP) tool: Acceptability, feasibility and potential role in enhancing clinical care of men with early-stage prostate cancer. JCO. 2016;34(15_suppl):e21631–e21631. doi: 10.1200/JCO.2016.34.15_suppl.e21631

8. Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, et al. Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol. 2014;191(3):638–45. doi: 10.1016/j. juro.2013.09.040

9. Skolarus TA, Dunn RL, Sanda MG, Chang P, Greenfield TK, Litwin MS, et al. Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form. Urology. 2015;85(1):101–5. doi: 10.1016/j. urology.2014.08.044

10. Gandaglia G, Tilki D, Zaffuto E, Fossati N, Pompe RS, Dell’Oglio P, et al. Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. European Urology Focus. 2019;5(4):545–9. doi: 10.1016/j. euf.2017.10.013

11. Ross LE, Howard DL, Bowie JV, Thorpe RJ, Kinlock BL, Burt C, et al. Factors Associated with Men’s Assessment of Prostate Cancer Treatment Choice. J Cancer Educ. 2016;31(2):301–7. doi: 10.1007/s13187-015-0837-9

12. van Stam M-A, Aaronson NK, Bosch JLHR, Kieffer JM, van der Voort van Zyp JRN, Tillier CN, et al. Patient-reported Outcomes Following Treatment of Localised Prostate Cancer and Their Association with Regret About Treatment Choices. Eur Urol Oncol. 2020;3(1):21–31. doi: 10.1016/j.euo.2018.12.004

13. D’Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostatespecific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17(1):168–72. doi: 10.1200/ JCO.1999.17.1.168

14. Hatzimouratidis K, Giuliano F, Moncada I, Muneer A, Salonia A, Verze P. Male sexual dysfunction. EUA Guidelines; 2018.

15. Balbontin F, Marchetti P, Moreno S, Cabello JM, Urzúa C, Silva A, et al. Calidad de vida en pacientes con cáncer de próstata: Validación de un instrumento para la práctica clínica. Archivos Españoles de Urología. 2015;68(5):466–73.

16. Donovan JL, Hamdy FC, Lane JA, Mason M, Metcalfe C, Walsh E, et al. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016;375(15):1425–37. doi: 10.1056/ NEJMoa1606221

17. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250–61. doi: 10.1056/ NEJMoa074311

18. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol. 2001;166(5):1804–10.

19. Pardo Y, Guedea F, Aguiló F, Fernández P, Macías V, Mariño A, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28(31):4687–96. doi: 10.1200/JCO.2009.25.3245.